In addition, a tumor microenvironment-activated nanoassembly that PD-L1 and CTLA-4 antagonistic aptamers are synthesized and co-assembly with glucose transporter 1 inhibitors has been demonstrated to significantly reduce PD-L1 N-linked glycosylation. This evidence concerns the gene CD274 and neoplasm.